*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.
Gilead Sciences is poised to capture investor attention as it approaches its earnings announcement on August 7, 2025, with a whisper number of $2.24 per share setting a high bar for expectations. This figure suggests that market insiders anticipate stronger performance than the consensus EPS estimate of $1.96, reflecting confidence in Gilead's ability to leverage its robust portfolio and strategic initiatives. With a substantial market cap of over $140 billion, Gilead's projected revenue of $6.97 billion will be closely scrutinized for signs of growth, particularly in its core therapeutic areas. Investors will be keen to see how Gilead navigates the competitive landscape and whether it can exceed the whisper number, which would signal a positive market sentiment and potentially drive share price momentum.
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.
Website: https://www.gilead.com
Average Sentiment Score:
Overall Sentiment: